immuno oncology frontiers world miami


Vamil K Divan

Dr Vamil K Divan

Senior Research Analyst, Credit Suisse LLC

Vamil Divan, MD has worked in equity research at Credit Suisse since 2007 and is now the Senior Analyst covering the U.S. Pharmaceutical sector. From 2011-2013 he led the Life Science Tools and Diagnostics team and prior to that he was a member of the U.S. Pharmaceuticals team. Before joining Credit Suisse, Vamil worked in the pharmaceutical industry. He was an Associate Director at Roche in Drug Safety and Risk Management and then a Medical Director at Pfizer with a focus on commercial products in neuroscience and inflammation. Vamil holds an MD degree from the University of Buffalo, an MBA from New York University. He did his Internal Medicine residency at Mount Sinai Medical Center in New York City and then was a practicing physician prior to joining the pharmaceutical industry.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy